Tim Kelly, PhD, CEO of RoosterBio, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco that ShiftBio will leverage RoosterBio's cell and media product portfolio as part of the collaboration.
"There's just a tremendous amount of interest and excitement about the potential of exosome therapies," Kelly said. "We believe that MSCs are really the optimal cellular source for exosomes, because you're getting all the therapeutic benefits of the MSC contained within that extracellular vesicle."
MSCs release lipid-bound extracellular vesicles, a broad category of tiny nano-sized particles including exosomes that mediate cell-to-cell communication, tissue homeostasis, and physiology.
Kelly also said that the industry is "anxiously awaiting" the U.S. Food and Drug Administration's approval of the first MSC-based therapy, which could happen within the next year.
Watch the video below to learn more.